New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
10:00 EDTRNA, PTCT, CBAY, SRPT, BIN, FLML, CWST, SGMO, PZG, FINL, ANET, SCMPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at Citigroup... Casella Waste (CWST) initiated with a Hold at Stifel... CymaBay Therapeutics (CBAY) initiated with an Outperform at Cowen... Finish Line (FINL) initiated with a Buy at Jefferies... Flamel Technologies (FLML) initiated with an Outperform at Leerink... PTC Therapeutics (PTCT) initiated with an Outperform at Oppenheimer... Paramount Gold & Silver (PZG) initiated with a Buy at Noble Financial... Progressive Waste (BIN) initiated with a Hold at Stifel... Prosensa (RNA) initiated with an Outperform at Oppenheimer... Sangamo (SGMO) initiated with an Overweight at JPMorgan... Sarepta (SRPT) initiated with an Outperform at Oppenheimer... Sucampo (SCMP) initiated with a Buy at Roth Capital.
News For ANET;CWST;CBAY;FINL;FLML;PTCT;PZG;BIN;RNA;SGMO;SRPT;SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 16, 2015
09:14 EDTANETArista Networks price target lowered to $80 from $115 at Pacific Crest
Pacific Crest cut its price target on Arista (ANET), citing increasing risks presented by the Cisco (CSCO) lawsuit. The firm keeps an Outperform rating based on valuation.
08:58 EDTFLMLFlamel Technologies price increase positive, says SunTrust
Subscribe for More Information
06:51 EDTANETArista Networks initiated with a Neutral at Buckingham
Target $70.
06:22 EDTCWSTCasella Waste upgraded to Overweight from Equal-Weight at First Analysis
January 15, 2015
15:26 EDTSRPTSarepta says no safety info or comparison in BioMarin presentation
Sarepta (SRPT) said that, given the small sample size of study 201/202, the company understood the importance of providing an "extensive amount of date" in order to understand eteplirsen's treatment effect. Sarepta has reported mITT data since week 24 and has continued to provide updates on this same mITT at every timepoint, the company said. BioMarin's (BMRN) presentation on Monday focused on extension phase and excluded dose-escalation phase and results during off-treatment periods, according to Sarepta. "Sarepta has regularly reported complete 201/202 safety data on all patients. No safety information or comparison [was included] in BioMarin's Monday presentation," Sarepta wrote in slides for its presentation at the JPMorgan Healthcare Conference.
14:17 EDTFINLFinish Line raises dividend 13% to 9c per share
Subscribe for More Information
12:26 EDTFLMLOn The Fly: Midday Wrap
Subscribe for More Information
11:20 EDTFLMLFlamel Technologies announces price increase for Bloxiverz
Subscribe for More Information
09:17 EDTFLMLFlamel Technologies weakness creates buying opportunity, says SunTrust
Subscribe for More Information
08:47 EDTFLMLFlamel Technologies price target lowered to $17 from $22 at Roth Capital
Roth Capital cut its price target on Flamel (FLML) after the FDA approved Fresenius Kabi's (FMS) New Drug Application for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz. Roth expects eostigmine to become a two player market, but adds that price increases by Flamel could mitigate the negative impacts on Flamel's growth. The firm keeps a Buy rating on Flamel.
08:43 EDTFLMLFlamel Technologies pullback an overreaction, says Summer Street
Subscribe for More Information
07:36 EDTFLMLFlamel Technologies sell-off yesterday overdone, says Leerink
Subscribe for More Information
07:13 EDTSRPTJPMorgan to hold a conference
Subscribe for More Information
January 14, 2015
16:33 EDTFLMLOn The Fly: Closing Wrap
Subscribe for More Information
14:10 EDTFLMLFlamel Technologies weakness a buying opportunity, says SunTrust
Subscribe for More Information
13:17 EDTFLMLFlamel says evaluating options after Kabi's NDA approval
Subscribe for More Information
12:49 EDTFLMLOn The Fly: Midday Wrap
Subscribe for More Information
12:09 EDTFLMLFlamel Technologies plunges after Jazz gets favorable patent ruling
Subscribe for More Information
08:30 EDTSRPTSarepta says first patient dosed in European Phase 1/II SRP-4053 study
Subscribe for More Information
January 13, 2015
08:53 EDTRNAProsensa announces holder approval of certain matters relating to BioMarin
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use